News & Events

Oncolytic viruses (OV) represent a transformative class of cancer therapeutics designed to selectively infect, replicate within, and destroy malignant cells while stimulating systemic antitumor immunity. Advances in genetic engineering have further enhanced the antitumor potential of OV by enabling the delivery of therapeutic payloads, improving tumor cell selectivity, and even evading neutralization by the host immune system.

Unlike conventional cytotoxic therapies, OV combine direct tumor lysis, immune activation, and drug delivery, positioning them at the intersection of virology, immunotherapy, and gene therapy. This multimodal mechanism of action offers a compelling strategy for the treatment of refractory cancers.

Over the past decade, the field has transitioned from experimental concepts to clinical reality, with regulatory approvals in major markets and a robust pipeline of candidates in late-stage development. However, the successful translation of OV from bench to bedside depends not only on biological innovation, but also on the establishment of robust, scalable, cost-effective, and GMP-compliant (cGMP) manufacturing platforms.